"Hypolipidemic Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
| Descriptor ID |
D000960
|
| MeSH Number(s) |
D27.505.519.186.071 D27.505.954.557.500
|
| Concept/Terms |
Hypolipidemic Agents- Hypolipidemic Agents
- Agents, Hypolipidemic
- Antihyperlipidemics
- Hypolipidemic Drugs
- Drugs, Hypolipidemic
- Antilipemic Drugs
- Drugs, Antilipemic
- Antilipemics
- Antihyperlipemics
- Antilipemic Agents
- Agents, Antilipemic
|
Below are MeSH descriptors whose meaning is more general than "Hypolipidemic Agents".
Below are MeSH descriptors whose meaning is more specific than "Hypolipidemic Agents".
This graph shows the total number of publications written about "Hypolipidemic Agents" by people in this website by year, and whether "Hypolipidemic Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 1 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 3 | 3 |
| 2003 | 1 | 2 | 3 |
| 2004 | 6 | 3 | 9 |
| 2005 | 0 | 3 | 3 |
| 2006 | 4 | 3 | 7 |
| 2007 | 5 | 2 | 7 |
| 2008 | 4 | 2 | 6 |
| 2009 | 6 | 2 | 8 |
| 2010 | 2 | 3 | 5 |
| 2011 | 4 | 3 | 7 |
| 2012 | 8 | 3 | 11 |
| 2013 | 6 | 3 | 9 |
| 2014 | 3 | 2 | 5 |
| 2015 | 8 | 0 | 8 |
| 2016 | 3 | 3 | 6 |
| 2017 | 1 | 2 | 3 |
| 2018 | 3 | 2 | 5 |
| 2019 | 3 | 0 | 3 |
| 2020 | 5 | 0 | 5 |
| 2021 | 3 | 1 | 4 |
| 2023 | 0 | 2 | 2 |
| 2024 | 1 | 1 | 2 |
| 2025 | 4 | 1 | 5 |
| 2026 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hypolipidemic Agents" by people in Profiles.
-
2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026 Apr 28; 153(17):e1154-e1276.
-
Screening, Diagnosis, and Management of Pediatric Hypertriglyceridemia: A Scientific Statement From the American Heart Association. Arterioscler Thromb Vasc Biol. 2026 04; 46(4):e000195.
-
Targeting Triglycerides in Cardiovascular Disease Prevention: Evidence, Mechanisms, and Emerging Therapies. Curr Cardiol Rep. 2026 Jan 03; 28(1):8.
-
Lipid-lowering therapies to target cardiac allograft vasculopathy after heart transplantation: Current evidence and future directions. J Clin Lipidol. 2026 Feb; 20(2):262-269.
-
The evolving landscape of targets for lipid lowering: from molecular mechanisms to translational implications. Eur Heart J. 2025 Nov 21; 46(44):4737-4750.
-
Targeting Triglycerides: The Rise of Apolipoprotein C3 and Angiopoietin-Like Protein 3 Inhibitors. Am J Cardiovasc Drugs. 2025 Nov; 25(6):749-766.
-
An overview of persistent chylomicronemia: much more than meets the eye. Curr Opin Endocrinol Diabetes Obes. 2025 Apr 01; 32(2):75-88.
-
The Association of Niacin Use with Kidney Outcomes and Mortality. Am J Nephrol. 2025; 56(4):457-467.
-
HDL Therapeutics - Time for a Curtain Call or Time to Reconceptualize? N Engl J Med. 2024 05 02; 390(17):1622-1623.
-
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol. 2024 May-Jun; 18(3):e308-e319.